6-K ·Filed Jul 30, 2026
Notable filing: 6-K
Actionable Insight ▲ Bullish
Monitor for initiation of Part B dosing in AUD patients and any subsequent data readouts.
Final — all horizons settled through T+60d
CMND ▼ -54.72% at T+60d
LONG call ✗ call lost -54.72% · α vs SPY -57.18% · entry $1.69 → $0.7652
T+1d
-3.55%
call -3.55% · α -4.97%
$1.63
settled 3mo ago
T+5d
-3.55%
call -3.55% · α -7.06%
$1.63
settled 3mo ago
T+20d
+4.14%
call +4.14% · α +1.15%
$1.76
settled 2mo ago
T+60d
-54.72%
call -54.72% · α -57.18%
$0.7652
settled 3d ago
Price Chart
Loading chart...
Executive Summary
Clearmind Medicine announced positive safety results from Part A of its Phase I/II trial for CMND-100, a non-hallucinogenic neuroplastogen-derived treatment for Alcohol Use Disorder. All 24 participants completed dose escalation up to 160 mg with no serious adverse events, meeting the primary safety endpoint.
Key Facts
- 24 participants across four ascending-dose cohorts (20, 40, 80, 160 mg) completed treatment per protocol.
- No serious adverse events observed; consistent tolerability at all dose levels.
- Primary endpoint of safety and tolerability achieved.
- Company intends to progress to subsequent stages including dosing AUD patients.
- Trial conducted at Yale, Johns Hopkins, Tel Aviv Sourasky, and Hadassah Medical Center.
Financial Impact
No financial data provided; positive safety data de-risks early-stage development but no revenue impact yet.
Risk Factors
- Clinical failure in later phases (efficacy not yet tested).
- Dilution risk from multiple F-3 shelf registrations referenced in the filing.
- Tiny market cap ($1M) amplifies volatility and liquidity risk.
- Forward-looking statements may not materialize.
Market Snapshot
Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-083320 |
| Document: ea0299819-6k_clearmind.htm | 0001213900-26-083320 |
| Document: 0001213900-26-083320-index-headers.html | 0001213900-26-083320 |
| Document: 0001213900-26-083320-index.html | 0001213900-26-083320 |
| Document: 0001213900-26-083320.txt | 0001213900-26-083320 |
63 reports for CMND
57% Hit rate @ T+60 Went positive at some point 15 of 20 best @ T+60▲ +75.73%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 10d ago | 6-K | $6.00 | awaiting T+60 | — | $6.12 (−2.02%) |
Oct 13, 2026 13d ago | 6-K | $6.23 | awaiting T+60 | — | $6.12 (−1.74%) |
Oct 8, 2026 18d ago | 6-K | $6.60 | awaiting T+60 | — | $6.12 (−7.25%) |
Oct 7, 2026 19d ago | 6-K | $6.60 | awaiting T+60 | — | $6.12 (−7.25%) |
Sep 23, 2026 4w ago | 6-K | $0.8500 | awaiting T+60 | — | $6.12 (+620.16%) |
Sep 23, 2026 4w ago | Press Release | $0.8500 | awaiting T+60 | — | $6.12 (+620.16%) |
Sep 17, 2026 5w ago | Press Release | $6.86 | awaiting T+60 | — | $6.12 (−10.82%) |
Sep 14, 2026 6w ago | 6-K | $0.9440 | awaiting T+60 | — | $6.12 (+548.45%) |
Sep 8, 2026 6w ago | 6-K | $1.03 | awaiting T+60 | — | $6.12 (+494.31%) |
Sep 4, 2026 7w ago | 6-K | $1.16 | awaiting T+60 | — | $6.12 (−427.71%) |
Showing 10 of 63
US Market Status
Market Closed — Opens Tue (< 1m)
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers